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S U M M A R Y
B A C K G R O U N D : Despite renewed focus on molecular
tuberculosis (TB) diagnostics and new antimycobacte-
rial agents, treatment outcomes for patients co-infected
with drug-resistant TB and human immunodeficiency
virus (HIV) remain dismal, in part due to lack of focus
on medication adherence as part of a patient-centered
continuum of care.
O B J E C T I V E : To review current barriers to drug-resis-
tant TB-HIV treatment and propose an alternative
model to conventional approaches to treatment support.
D I S C U S S I O N : Current national TB control programs
rely heavily on directly observed therapy (DOT) as the
centerpiece of treatment delivery and adherence support.
Medication adherence and care for drug-resistant TB-
HIV could be improved by fully implementing team-
based patient-centered care, empowering patients
through counseling and support, maintaining a rights-
based approach while acknowledging the responsibility
of health care systems in providing comprehensive care,
and prioritizing critical research gaps.
C O N C L U S I O N : It is time to re-invent our understanding
of adherence in drug-resistant TB and HIV by focusing
attention on the complex clinical, behavioral, social, and
structural needs of affected patients and communities.
K E Y W O R D S : drug-resistant TB; HIV; medication
adherence; patient-centered care
APPROXIMATELY 1.5 MILLION people are living
with multidrug-resistant tuberculosis (MDR-TB)
worldwide. While the overall TB epidemic is very
slowly being brought under control, the number of
TB patients with drug-resistant TB (DR-TB) contin-
ues to rise. In 2013 alone, the World Health
Organization (WHO) estimated that 480 000 indi-
viduals developed MDR-TB, an increase of 80%
from 2000 estimates.1 Globally, MDR-TB is associ-
ated with human immunodeficiency virus (HIV)
infection,2 and HIV exacerbates TB clinically and in
terms of social impact.3 In South Africa, the epicenter
of the drug-resistant TB-HIV syndemic, up to 80% of
patients with extensively drug-resistant TB (XDR-
TB) are HIV co-infected. Even in low HIV burden
countries, the proportion of DR-TB patients with
HIV co-infection ranges between 7% and 23%.4,5
Treatment of DR-TB in low- and middle-income
settings is fraught with clinical, operational and social
challenges. Patients with DR-TB/HIV take an average
of six antimycobacterial medications for .18 months
in addition to lifelong antiretroviral therapy (ART).
Treatment is often centralized, and involves social
marginalization, family isolation, difficult and pain-
ful treatment regimens, dual stigmatization, and
economic loss.3,6,7 In contrast, drug-susceptible TB
is typically treated over a period of 6 months, with far
fewer and far less toxic medications, through largely
decentralized channels of care. While recent innova-
tions in TB diagnostics, such as the Xpertw MTB/RIF
Correspondence to: Max O’Donnell, Department of Epidemiology, Mailman School of Public Health, Columbia University,
Suite E101, 622 W 168th St, PH Building, New York, NY 10032, USA. e-mail: mo2130@columbia.edu
Article submitted 3 May 2015. Final version accepted 27 October 2015.
assay (Cepheid, Sunnyvale, CA, USA), have enhanced
MDR-TB case detection, cure rates remain appall-
ingly low.1 Poor treatment outcomes have a number
of potential causes. Low levels of medication
adherence are predicted to be an important cause of
treatment failure,8,9 and are strongly associated with
failure to convert TB culture to negative during
treatment.8–10
Medication adherence in ART has been carefully
studied.11 Each medication has a defined adherence-
resistance relationship, which is a function of the
potency of the medication and replicative capacity of
drug-resistant organisms. Time on ART as well as
patterns of treatment interruptions also influence
drug resistance-induced treatment failure.11–13 In
contrast to HIV, medication adherence in DR-TB-
HIV is substantially understudied.14–18 Preliminary
research from South Africa finds that XDR-TB/HIV
co-infected patients report significantly lower adher-
ence to TB medications than ART.10 High ART
adherence with low TB medication adherence may
improve patient survival without improving TB
treatment outcomes,19 and contribute to ongoing
transmission.
Although the WHO has endorsed more progressive
approaches, such as the International Standards for
Tuberculosis Care,20,21 the reality is that anti-
tuberculosis treatment programs around the world
focus on directly observed therapy (DOT) as the
centerpiece of treatment delivery and adherence
support. As an isolated intervention, DOT lacks a
rigorous evidence base and is often at odds with
patient needs and preferences.3,22–24 From the health
systems perspective, DOT programs may integrate
poorly into health systems, face technical challenges
and variability of access, and poorly address stig-
ma.24–26 To improve adherence in DR-TB/HIV, there
is an urgent need to evaluate patient-centered care
approaches that look beyond DOT, in particular its
conventional facility-based form. Although HIV care
delivery can inform future advances in TB manage-
ment, long-term HIV management itself requires
paradigm shifts from centralized to decentralized,
patient-focused approaches that address the waiting
times for ART refills, improved management of
medical complications, transportation barriers, and
burden on the strained health care workforce.25
A patient-centered approach to adherence in DR-TB
and HIV treatment that reflects the Institute of
Medicine (Washington DC, USA) recommendation
for ‘partnership among practitioners, patients, and
their families (when appropriate) to ensure that
decisions respect patients’ wants, needs, and prefer-
ences and that patients have the education and support
they need to make decisions and participate in their
own care’ is imperative.26,27 In other words, not only
should we recognize the time, cost and quality of
health care services, we should also consider the
patient’s perspective and build on patient-provider
relationships to enhance the humaneness of care
through communication, shared decision-making and
support for self-management. Patient-centered care
has been shown to have positive effects on patient
behavior, well-being, and treatment outcomes.28 For
treatment of DR-TB and HIV, successful programs
have included important elements of patient-centered
care, including emphasizing patient preference; decen-
tralized, community-based care;29 and intensive coun-
seling, accompaniment,30 and support; while
programs using mostly conventional models of care
have shown poor outcomes.31
We conceptualize patient-centered care as being
oriented toward addressing patients’ priorities, not in
the sense of a menu of choices, but rather as a holistic
model of health care delivery that considers the
patient as the central figure in the process or
continuum of care. A patient-centered approach is
therefore not a one-size-fits-all solution to the
multifactorial patient-related barriers to MDR/
XDR-TB/HIV treatment adherence that have been
identified, including high TB pill burden and adverse
drug effects, lack of patient education and counseling,
provider supervision of anti-tuberculosis treatment,
inability to access care in the community, and the
stigma of public TB notification.3,7,10 Conversely, a
patient-centered approach is a flexible model of care
that reacts to the specialized needs of individuals.
Studies of DR-TB/HIV co-infected patients have
identified HIV-specific services as facilitators of
ART adherence, including treatment literacy coun-
seling, patient involvement in care, and simpler drug
regimens.3,32
Patient-centered care depends on engaging each
individual patient with tailored education/counseling,
understanding their motivations, and enhancing
behavioral skills within the context of local social,
structural and cultural factors. A patient-centered
approach is particularly critical in vulnerable and
marginalized MDR-/XDR-TB patients. The current
model of care in much of the world, which relies on a
clinician to examine the MDR-TB/HIV patient and
prescribe TB medications without input from coun-
selors, social workers or mental health professionals,
much less patients, addresses very little of this
vulnerability. A team-based approach that includes
mental health trained providers, social work trained
providers, and behavioral counselors who can engage
with patients more directly and holistically, and
explicitly integrates HIV and DR-TB care, allows us
to think about and make treatment decisions that
encompass the full range of clinical, socio-economic
and structural issues confronting patients.
Patient-centered approaches recognize that compre-
hensive care must be provided along a locally
contextualized continuum of services. The continuum
or cascade of care for DR-TB/HIV describes the
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complex, integrated steps from diagnosis to cure. In
DR-TB/HIV, this should incorporate early TB diagno-
sis and drug susceptibility testing, early HIV diagnosis,
comprehensive patient education and support, infec-
tion control, streamlined entry into co-treatment,
unimpeded access to medications, adherence support,
and retention in dual care. For patients cured of DR-
TB, the cascade should conclude with support for
reintegration back into the community, family life, and
employment. For patients with disease considered
incurable, it must include palliative care (Figure). The
decline between steps in the continuum represents
patient attrition, and underscores the need to improve
care and retention at each step.
In March 2015, a meeting of clinicians, behavioral
and social scientists, patients, and activists convened
at the Mailman School of Public Health, Columbia
University, New York, NY, USA, to generate a call to
action for patient-centered care in the treatment of
DR-TB/HIV. We commit to working with affected
communities to improve medication adherence by re-
inventing models of care delivery that respect and
address patients’ needs. This commitment is based on
the following principles that emerged from the 2015
symposium:
1 Patient-centered care is team-based, decentralized
care that requires substantial investment in human
resources to provide high-quality care in settings
where patients live and work, and are connected to
networks of social capital and social support.
2 Patient education and counseling—with the goals
of patient empowerment, treatment literacy, ac-
countability, and reducing stigma—should be at the
heart of adherence support for DR-TB/HIV. Core
standards in counseling and education for DR-TB/
HIV need to be developed, as education and DOT
may have different meanings and are implemented
differently throughout the world.
3 Public health approaches to DR-TB/HIV should be
based on human rights and equity. Where public
health and individual rights conflict—for example,
the forcible detention or isolation of people with
infectious XDR-TB to protect others from trans-
mission—a rights-based approach will use deliber-
ation in accordance with the Siracusa Principles33
to justify rights-limiting public health measures.
4 Patient-centered care does not mean centering all
responsibility on the person with TB. Grounding
patient-centered care in rights-based approaches
recognizes that governments and health systems
must bear the responsibility to respect, protect, and
fulfill the right to health along the cascade of care.
5 There are critical research gaps in understanding
the cascade of care for DR-TB/HIV, including
biomedical, behavioral, and implementation sci-
ence components. This research agenda must be
urgently prioritized in parallel with operationaliz-
Figure The continuum of DR-TB/HIV care defines the processes and linkages that comprise
optimal care for MDR-/XDR-TB/HIV. The y-axis represents patients retained in care; the x-axis
represents the stages of the continuum; the arrows represent the linkages in the continuum. The
box below defines tasks and processes that occur at each stage. TB¼ tuberculosis; HIV¼ human
immunodeficiency virus; DR-TB ¼ drug-resistant TB; VL ¼ viral load; DST ¼ drug susceptibility
testing; MDR-TB¼multidrug-resistant TB; XDR-TB¼ extensively drug-resistant TB. This image can
be viewed online in colour at http://www.ingentaconnect.com/content/iuatld/ijtld/2016/
00000020/00000004/art00004
432 The International Journal of Tuberculosis and Lung Disease
ing patient-centered practices, and donors should
commit to funding this research.
The development of new TB diagnostics, drugs,
and treatment regimens presents exciting opportuni-
ties to improve outcomes and reduce community
transmission of DR-TB. With innovative and effective
approaches to patient-centered care, the opportunity
to impact the epidemic afforded by new diagnostics
and drugs may not be realized. It is time for clinicians,
researchers and TB practitioners to re-invent the
understanding of adherence in DR-TB/HIV to elim-
inate disease and stigma by focusing efforts and
attention on affected patients and communities.
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R E S U M E
C O N T E X T E : En dépit d’une attention renouvelée au
diagnostic moléculaire de la tuberculose (TB) et de la
disponibilité de nouveaux agents antimycobactériens, le
résultat du traitement des patients co-infectés
par une TB pharmacorésistante et par le virus de
l’immunodéficience humaine (VIH) restent affligeants,
en partie par manque d’attention vis-à-vis de l’adhésion
aux médicaments dans le cadre d’une continuité des
soins centrée sur le patient.
O B J E C T I F : Revoir les obstacles actuels au traitement de
la TB-VIH pharmacorésistante et proposer un modèle
alternatif aux approches conventionnelles du soutien au
traitement.
D I S C U S S I O N : Actuellement, les programmes
nationaux de lutte contre la TB s’appuient fortement
sur le traitement sous observation directe (DOT) comme
pièce maı̂tresse de la prestation du traitement et comme
soutien à l’adhésion. L’adhésion aux médicaments et la
prise en charge de la TB-VIH pharmacorésistante
pourraient cependant être améliorées par la mise en
œuvre complète d’une prise en charge centrée sur le
patient par une équipe, autonomiser les patients grâce à
des conseils et du soutien, maintenir une approche basée
sur les droits tout en reconnaissant la responsabilité du
système de santé en ce qui concerne l’ensemble de la prise
en charge et l’établissement des priorités en matière de
besoins cruciaux dans le domaine de la recherche.
C O N C L U S I O N : Il est temps de réinventer notre
compréhension de l’adhésion au traitement de la TB-
VIH pharmacorésistante en concentrant notre attention
sur les besoins complexes cliniques, comportementaux,
sociaux et structurels des patients affectés et de leurs
communautés.
R E S U M E N
M A R C O D E R E F E R E N C I A: Pese a un interés renovado en
los métodos diagnósticos moleculares de la tuberculosis
(TB) y en los nuevos medicamentos antituberculosos, los
desenlaces terapéuticos de los pacientes coinfectados por
el virus de la inmunodeficiencia humana (VIH) y el
bacilo de la TB farmacorresistente siguen siendo muy
desfavorables, en parte debido a la falta de refuerzo del
cumplimiento terapéutico, como un componente
integral de la continuidad asistencial centrada en el
paciente.
O B J E T I V O: Examinar los obstáculos actuales al
tratamiento de la coinfección por el VIH y la TB
farmacorresistente y proponer una nueva opción a las
estrategias convencionales de apoyo al tratamiento.
D I S C U S I Ó N: En la actualidad, los programas nacionales
contra la TB aplican el tratamiento breve directamente
observado (DOT), como pilar central de la
administración del tratamiento antituberculoso y de
apoyo al cumplimiento terapéutico; es posible mejorar la
adhesión al tratamiento y la atención de la coinfección
por el VIH y la TB farmacorresistente con las siguientes
medidas: la plena adopción de una atención prestada por
equipos del personal de salud y centrada en el paciente,
la promoción de la corresponsabilización de los
pacientes mediante el asesoramiento y el apoyo, el
mantenimiento de un enfoque basado en los derechos y
al mismo tiempo el reconocimiento de la responsabilidad
de los sistemas de atención de salud en la prestación de
una atención integral y la priorización de las principales
lagunas de la investigación.
C O N C L U S I Ó N: Llegó el momento de reinventar nuestro
concepto del cumplimiento terapéutico en los casos de
infección por el VIH y la TB farmacorresistente,
centrando la atención en las complejas necesidades
clı́nicas, comportamentales, sociales y estructurales de
los pacientes y las comunidades afectados.
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